More than 100 countries/regions around the world have extended COVID-19 vaccination activities to children.
According to a UNICEF report, the report analyzed 115 million confirmed COVID-19 cases from 105 countries, and people under the age of 20 accounted for 16% of the reported cases.
Although many children infected with COVID have almost no symptoms, those with underlying health problems may be at increased risk of serious illness.
Three vaccines approved by the World Health Organization (WHO) are being used for child vaccination in various countries/regions: Pfizer-BioNTech vaccine, Sinopharm injection and Sanova vaccine.
Some countries provide a complete course of two doses of Pfizer-BioNTech vaccine for children and adolescents, while others provide a single dose.
According to data from the London School of Hygiene and Tropical Medicine, 20 vaccine candidates are undergoing clinical testing for children under 18 years of age.
China has begun to vaccinate children aged 3 years and above with its own CoronaVac vaccine produced by China Huaxing Biotechnology Company.
Taiwan has suspended the provision of a second dose of Pfizer’s BioNTech vaccine to children and adolescents between the ages of 12 and 17 due to concerns about the risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer membrane of the heart).To the media report.
In August, the Indian drug regulatory agency approved Zydus Cadila’s needle-free ZyCoV-D vaccine, which is suitable for people 12 years and older. It is the world’s first DNA platform vaccine for COVID-19, but it has not yet begun to roll out. Bharat Biotech, the maker of the domestically produced Covaxin vaccine, is seeking emergency use in children 12 years and older, but the regulatory agency has not yet announced a decision.News reports say that vaccination for certain groups of children may start in January Say.
Pakistan is currently vaccinating children over 15 years old with Pfizer-BioNTech vaccine, and children over 12 years old with vaccines from China’s Sanova and Sinopharm.
South Africa began immunizing children between 12 and 17 years of age in October. The government’s goal is to vaccinate approximately 6 million young people of this age with a dose of Pfizer-BioNTech vaccine.
Morocco is one of the first African countries to provide vaccinations to children and adolescents. It began vaccinating children between 12 and 17 years old in September. It is using vaccines from Pfizer BioNTech and Sinopharm, with the aim of vaccinating at least 3 million children.
The European Medicines Agency (EMA), the European Union’s health regulator, approved the use of Pfizer-BioNTech vaccine for children over 12 years of age in May.
In Germany, as of November 23, approximately 45% of the 12 to 17-year-old age group had been fully vaccinated with Pfizer’s BioNTech vaccine.
In Norway, which is not part of the European Union, Pfizer’s BioNTech vaccine has been approved for people between 12 and 15 years of age. But health authorities have suspended the introduction of the second dose, partly because of rare side effects related to heart inflammation.
In the UK, which is not part of the European Union, people aged 12 to 15 are receiving a single injection of Pfizer BioNTech.
EU regulators are evaluating applications to expand the use of the vaccine to children aged 5 to 11 years. An announcement is expected next month.
In September, Cuba began to introduce vaccines for children as young as two years old, including domestically produced Soberana-02 and Soberana Plus vaccines.
In Venezuela, the authorities announced in early November that they were using the Cuban Soberana-02 vaccine to vaccinate children as young as two years old.
Brazilian health regulator Anvisa has approved the use of Pfizer’s BioNTech vaccine in children aged 12 to 17, and the government encourages local authorities to give priority to children and adolescents with comorbidities.
The United Arab Emirates began vaccinating children from 3 to 11 years old with Sinopharm vaccine in August. In November, UAE authorities approved the Pfizer-BioNTech vaccine for children aged 5 to 11.
In October, Bahrain authorized children aged 3 to 11 to use Sinopharm injections. This month, Bahrain approved Pfizer’s BioNTech for use in children aged 5 to 11.
In May of this year, the US health authorities approved the Pfizer-BioNTech vaccine for use in children aged 5 to 17.
Since the outbreak, Child representative According to data from the American Academy of Pediatrics, it accounts for 16.9% of all confirmed cases. In the week ending November 18, children accounted for 25.1% of reported cases. Children account for 22.2% of the U.S. population.